Bharat Biotech awaits DCGI nod to launch Covaxin for children

We now await further regulatory approvals from the CDSCO prior to product launch and market availability of Covaxin for children.

89
DCGI CDSCO

Last Updated on October 13, 2021 by The Health Master

After getting approval from the Subject Expert Committee (SEC) for Covaxin to be used for children in the two-to-18 years of age group with certain conditions, Bharat Biotech today said they are awaiting further regulatory approvals from the Central Drugs Standard Control Organisation (CDSCO) to launch the product.

The expert panel of India’s Central Drug Authority has recommended granting Emergency Use Authorisation (EUA) to Bharat Biotech’s Covaxin for children in the two-to-18-year age group with certain conditions.

“This represents one of the first approvals worldwide for C-19 vaccines for the two-to-18-year age group. Bharat Biotech sincerely thanks the DCGI, Subject Experts Committee and CDSCO for their expedited review process.

We now await further regulatory approvals from the CDSCO prior to product launch and market availability of Covaxin for children,” Bharat Biotech said in a statement.

The company has submitted data from clinical trials in the two-to-18-year age group for Covaxin (BBV152) to CDSCO.

The data has been thoroughly reviewed by the CDSCO and SEC who have provided their positive recommendations, the vaccine maker said.

The SEC on C-19 examined the data and deliberated on the EUA application yesterday.

“After detailed deliberation, the committee recommended grant of market authorisation of the vaccine for the age group of two-to-18 years for restricted use in emergency situations subject to the certain conditions,” the SEC recommendations stated.

The recommendations have been forwarded to the Drugs Controller General of India (DCGI) for final approval.

Molbio gets DCGI nod for Truenat Scrub T test for Scrub Typhus

DCGI gives permission to conduct Phase III trial for two-dose C-19 vaccine

DCGI allows Serum Institute for Vaccine trial on kids aged 7-11 years

DCGI’s nod to AstraZeneca to import, market Selumetinib Capsules

DCGI nod to BDR Pharma for drug to treat various infections

DCGI approves Clinical Trial of MESOCEL therapy to treat COVID

Covishield

Covaxin

Sputnik V

Modenra

Latest Notifications: Homoeopathic

Molbio gets DCGI nod for Truenat Scrub T test for Scrub…

World’s first Rapid Test Kit for lung disease developed in India

Govt allows export of Sputnik Light made in India

AiMeD asks Govt to frame separate Act for Medical Devices

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner